Kventiax (Quetiapine)

Quetiapine blocks serotonin 5‑HT2A and dopamine D2 receptors while partially stimulating 5‑HT1A receptors and antagonising histamine H1 and alpha‑adrenergic sites. This mixed activity balances neurotransmission, reducing psychotic symptoms and stabilising mood.

The appropriate dose of Kventiax is determined by the prescribing clinician based on the individual’s diagnosis, severity of symptoms, age, and response to therapy. Dosage adjustments are made according to clinical judgment and patient tolerance.

Safety data for quetiapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Kventiax, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kventiax (quetiapine) offers a broader receptor profile, including strong antihistamine and alpha‑adrenergic blockade, which can lead to more pronounced sedation and metabolic effects compared with agents such as risperidone. Choice of therapy depends on individual symptom patterns, side‑effect tolerability and clinician preference.

Kventiax should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Kventiax is taken orally as a tablet. It should be swallowed whole with water and can be taken with or without food, following the dosing schedule prescribed by the treating physician.

Serious risks include neuroleptic malignant syndrome, severe hypotension, and QT interval prolongation that may predispose to cardiac arrhythmias. Patients should be monitored closely for signs of these conditions, especially during dose changes or when combined with interacting medications.

Kventiax is contraindicated in individuals with known hypersensitivity to quetiapine or any of its excipients. Caution is advised in patients with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of neuroleptic malignant syndrome.